Staphylococcus Or Streptococcus (e.g., Pneumococcus Or Streptococcus Pneumoniae, Streptococcus Mutans, Etc.) Patents (Class 424/165.1)
-
Patent number: 7687278Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of Streptococci mutans by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of Streptococci mutans in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and Streptococci mutans from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.Type: GrantFiled: April 13, 2006Date of Patent: March 30, 2010Assignee: GC CorporationInventor: Atsushi Tachino
-
Publication number: 20100015138Abstract: The present invention discloses crystal structure of Staphylococcus aureus Clumping factor A (ClfA) in complex with fibrinogen (Fg) derived peptide. Also, the present invention also discloses the use of this structure in the design of ClfA targeted vaccines and therapeutic agents (including monoclonal antibodies). In addition, the present invention discloses isolated and purified engineered Staphylococcus clumping factor A protein (ClfA) with a stabilized, closed conformation and immunogenic compositions thereof including methods of treating a Staphylococcus infection in an individual.Type: ApplicationFiled: June 30, 2009Publication date: January 21, 2010Inventors: Magnus Hook, Ya-Ping Ko, Emanuel Smeds, Yannakambadi K. Ganesh
-
Patent number: 7648830Abstract: A method is provided for determining the presence of a target bacteria based on its resistance to a cell lysing antibiotic. Said antibiotic is used to lyse cells of non-target bacteria in a sample and hence facilitate isolation of the target prior to detection by known means.Type: GrantFiled: September 2, 2002Date of Patent: January 19, 2010Assignee: The Secretary of State for Defence in Her Britannic Majesty's Government of the United Kingdom of Great Britain and Northern IrelandInventors: David James Squirrell, Rachel Louise Leslie, Kevin J Bown
-
Patent number: 7625561Abstract: Common oral diseases such as periodontitis and dental caries can be prevented effectively by passive immunization. The present invention provides human single chain Fv (scFv) and diabody antibody fragments based on the binding characteristics of the murine monoclonal antibody Guy's 13. Like the parent antibody, these derivatives bind specifically to SAI/II, the surface adhesin of Streptococcus and the human diabody derivative is capable of aggregating streptococcal cells, making it a useful candidate therapeutic agent for passive immunization against oral diseases.Type: GrantFiled: April 21, 2005Date of Patent: December 1, 2009Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.Inventors: Ricarda Finnern, Rainer Fischer
-
Publication number: 20090274704Abstract: A pharmaceutical composition includes a purified antibody and a pharmaceutically acceptable carrier. The antibody is enriched for immunoglobulins having both an antigen-binding portion that binds a Staphylococcus aureus capsular polysaccharide antigen and a constant region that does not bind staphylococcal protein A.Type: ApplicationFiled: July 2, 2009Publication date: November 5, 2009Applicant: STROX Biopharmaceuticals, LLCInventor: Stanley Arthur Kim
-
Patent number: 7588920Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: January 23, 2007Date of Patent: September 15, 2009Assignee: WyethInventors: Lynn Doucette-Stamm, David Bush
-
Publication number: 20090162379Abstract: Provided herein is a method for identifying small molecule inhibitors of S. aureus SdrD protein attachment to a host cell receptor using a structural model of SdrD protein-receptor interaction. Also provided are the small molecule inhibitors so identified and synthetic small molecules effective to bind SdrD protein and/or the host cell receptor. In addition, antibodies directed against SdrD protein are provided. Further provided are methods of treating or preventing S. aureus associated lung infections and of inhibiting S. aureus adherence to a lung cell using the small molecules and antibodies described herein.Type: ApplicationFiled: October 1, 2008Publication date: June 25, 2009Inventors: Magnus Hook, Elena M. Barbu
-
Patent number: 7531633Abstract: A negatively-charged Staphylococcus antigen contains amino acids and a N-acetylated hexosamine as a major carbohydrate component. The antigen is common to many coagulase-negative strains of Staphylococcus, including S. epidermidis, S. haemolyticus, and S. hominis. Staphylococcus strains that carry the antigen include many clinically significant strains of Staphylococcus. The antigen and antibodies to the antigen are useful in kits and assays for diagnosing Staphylococcus infection. Vaccines of the antigen and of whole cells that carry the antigen also are disclosed.Type: GrantFiled: December 20, 2004Date of Patent: May 12, 2009Assignee: Nabi BiopharmaceuticalsInventors: Viliam Pavliak, Ali Ibrahim Fattom
-
Publication number: 20090081236Abstract: The present invention provides compositions including siderophore receptor polypeptides and porins from gram negative microbes, and preferably, lipopolysaccarhide at a concentration of no greater than about 10.0 endotoxin units per milliliter. The present invention also provides methods of making and methods of using such compositions.Type: ApplicationFiled: April 11, 2008Publication date: March 26, 2009Applicant: Epitopix, LLCInventors: Daryll A. Emery, Darren E. Straub
-
Publication number: 20090074755Abstract: The present invention relates to compositions and methods for treating Staphylococcus aureus (S. aureus) infections. In particular, the present invention provides vaccines comprising a Panton-Valentine Leukocidin (u) antigen, antibodies which bind a PVL antigen and compositions containing the same, methods of making such compositions and methods for treating S. aureus infections, including those that are community acquired methicillin-resistant infections. The present invention also provides PVL antibodies, including PVL antibodies specific for a single PVL subunit, and PVL antigens, including conjugated and mutated PVL antigens.Type: ApplicationFiled: June 13, 2006Publication date: March 19, 2009Inventors: Kimberly Louise Taylor, Ali Ibrahim Fattom
-
Publication number: 20090053235Abstract: Vaccines comprising an S. aureus alpha-toxin antigen and a pharmaceutically acceptable carrier are provided, and are useful for treating and preventing infections. The S. aureus alpha-toxin antigen may contain at least two alterations that reduce its toxicity and/or may be conjugated to or co-administered with another bacterial antigen. The vaccines may comprise one or more other bacterial antigens. Antibody compositions comprising antibodies to alpha-toxin and optionally one or more other bacterial antigens also are provided, and are useful for treating and preventing infections.Type: ApplicationFiled: February 27, 2007Publication date: February 26, 2009Inventors: Kimberly L. Taylor, Ali I. Fattom
-
Publication number: 20090041782Abstract: A polynucleotide encoding a polypeptide which lowers the glucose side chain amount in a serotype-specific polysaccharide antigen of Streptococcus mutans; novel Streptococcus mutans strain having the above polynucleotide; an antibody specific to this Streptococcus mutans strain; and a method of detecting the above-described Streptococcus mutans strain occurring in a subject sample. According to this method, it is possible to examine the presence or absence of Streptococcus mutans of an untypable serotype in a subject sample to thereby specify a subject having a high risk of the onset of infective endocarditis.Type: ApplicationFiled: December 28, 2004Publication date: February 12, 2009Inventors: Takashi Ooshima, Kazuhiko Nakano
-
Publication number: 20090010929Abstract: The present invention provides compositions, including pharmaceutical compositions, comprising an amount of an antibody, antibody fragment or antibody conjugate sufficient to treat Group A streptococcus (GAS) infection or complication thereof in a subject or a disease or complication associated with GAS infection in a subject wherein said antibody, antibody fragment or antibody conjugate binds immunospecifically to a B-cell epitope of GAS M-protein. The present invention also provides methods for the prophylactic or therapeutic treatment of infection by GAS and complications thereof comprising administering the compositions to a subject in need thereof.Type: ApplicationFiled: December 4, 2007Publication date: January 8, 2009Inventors: Michael F. Good, Michael R. Batzloff, Manisha Pandey
-
Publication number: 20080311129Abstract: A method for the production of antibodies or microbial adherents administers is disclosed. The antibodies or microbial adherents inhibitors are administered to a patient suffering from strep throat to substantially prevent the adherents of colony-forming immunogens or haptens in the throat of the patient. Application of the antibodies should decrease the colonization of the oropharnyx, and therefore decrease symptoms of the sore inflamed throat and ultimately decrease the need for antibiotics.Type: ApplicationFiled: November 1, 2007Publication date: December 18, 2008Applicant: Camas IncorporatedInventors: Peter Nash, Bradley M. Mitteness, Michael O'Rourke
-
Patent number: 7438912Abstract: The present invention discloses isolated nucleic acid molecules encoding a hyperimmune serum reactive antigen or a fragment thereof as well as hyperimmune serum reactive antigens or fragments thereof from S. agalactiae, methods for isolating such antigens and specific uses thereof.Type: GrantFiled: May 6, 2004Date of Patent: October 21, 2008Assignee: Intercell AGInventors: Andreas Meinke, Eszter Nagy, Markus Hanner, Markus Horky, Sabine Kallenda, Sonja Prustomersky
-
Publication number: 20080171054Abstract: The present invention is concerned with novel antibodies, medicaments, pharmaceutical packs, methods of manufacture of medicaments and methods for the treatment of micro-organism infections, particularly for the treatment of Staphylococcal infections such as S. aureus infections including MRSA infections.Type: ApplicationFiled: October 31, 2007Publication date: July 17, 2008Inventors: James Peter Burnie, Ruth Christine Matthews
-
Publication number: 20080171053Abstract: A number of immunologically active agents are described, including an isolated protein or polypeptide that includes the amino acid sequence of SEQ ID NO: 1, immunogenic conjugates containing either the protein or polypeptide, a full-length Pneumocystis kexin, or a full length Streptococcus pneumoniae pneumococcal surface protein A (PspA), antibodies recognizing the protein or polypeptide or the immunogenic conjugates (particularly the epitope of SEQ ID NO: 1), and nucleic acid molecules that encode the protein or polypeptide, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a patient.Type: ApplicationFiled: December 31, 2004Publication date: July 17, 2008Inventors: Francis Gigliotti, Terry W. Wright, Constantine G. Haidaris, Patricia J. Simpson-Haidaris, Jesse Wells
-
Patent number: 7368112Abstract: The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus CIfA protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound healing, blocking adherence to indwelling medical devices, or diagnosis of infection.Type: GrantFiled: February 7, 2006Date of Patent: May 6, 2008Assignee: The Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near DublinInventors: Timothy James Foster, Damien Leo McDevitt
-
Patent number: 7364738Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: May 25, 2005Date of Patent: April 29, 2008Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 7316910Abstract: A reagent for the detection of an extracellular enzymatically active protein produced by a beta-hemolytic streptococcus bacteria found in a host biological fluid includes a proteinaceous substrate or a cholesterol-containing membrane substrate for the extracellular protein. The substrate is nonspecific within the groups of beta-hemolytic streptococcus bacterium and is in contact with an inert solid matrix. Upon reaction between the streptococcus enzymatically activate protein and the substrate, a color change discernable by an unaided human eye results. Extracellular streptococcus protein found in saliva represents a less invasive source of biological fluid for the determination as to whether a host suffers acute pharyngitis.Type: GrantFiled: June 2, 2005Date of Patent: January 8, 2008Assignee: Kinase Scientific, LLCInventors: Leroy E. Mosher, Craig J. Bell
-
Patent number: 7279162Abstract: The invention describes the identification, making, and isolation of immunoglobulin and antigen useful for preventing, diagnosing, and treating staphylococcal infections. The invention further describes an in vivo animal model useful for testing the efficacy of pharmaceutical compositions, including pharmaceutical compositions of immunoglobulin and isolated antigen.Type: GrantFiled: June 6, 1995Date of Patent: October 9, 2007Assignee: Henry M. Jackson Foundation for the Advancement of Military MedicineInventor: Gerald W. Fischer
-
Patent number: 7241592Abstract: Antibodies to the CNA protein and to other regions from the collagen binding domain, including domain CNA19, are provided, and antibodies produced in this manner have been shown to be cross reactive to both Staphylococcus aureus and Staphylococcus epidermidis bacteria and which can thus be used in the prevention and treatment of infections caused by both of these types of bacteria. In addition, medical instruments can be treated using the antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the proteins are advantageous because they are cross-reactive and may thus be administered to patients so as to reduce or prevent severe infection by staphylococcal bacteria of more than one species.Type: GrantFiled: March 19, 2001Date of Patent: July 10, 2007Assignees: Universita Degli Studi di Pavia, The Texas A&M University System, Inhibitex, Inc.Inventors: Magnus Hook, Yi Xu, Pietro Speziale, Livia Visal, Fabrizia Casolini, Joseph M. Patti, Pratiksha Patel, Paul Domanski
-
Patent number: 7238351Abstract: The method of producing a microbial adherence inhibitor for administration to food animals to control the incidents of acidosis in food animals by preventing the adherence of colony-forming lactic acid producing bacteria in the rumen or intestinal tracts of the food animals. The method includes inoculating female birds in or about their egg laying age with a lactic acid producing bacteria that colonizes in the intestinal tract of the food animal to be treated. Allowing a period of time sufficient to permit the production in the birds of antibody to the lactic acid producing bacteria and harvesting the eggs laid by such birds. The antibody-containing contents of the eggs are then separated by the shells.Type: GrantFiled: September 8, 2003Date of Patent: July 3, 2007Inventors: Peter Nash, Bradley M. Mitteness
-
Patent number: 7226590Abstract: This invention provides novel Streptococcus salivarius, compositions containing same, and use of S. salivarius strains as antimicrobial agents. The strains are bacterial inhibitors with respect to at least S. mutans and/or MS and therefore have a number of therapeutic applications. The applications include but are not limited to forming part of therapeutic formulations for use in controlling, treating, or preventing dental caries.Type: GrantFiled: February 21, 2003Date of Patent: June 5, 2007Assignee: BLIS Technologies LimitedInventors: Christopher Norman Chilcott, John Robert Tagg
-
Patent number: 7195763Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAVVEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.Type: GrantFiled: August 5, 2004Date of Patent: March 27, 2007Assignee: The Texas A & M Univerisity SystemInventors: Yi Xu, Magnus A. O. Hook
-
Patent number: 7189404Abstract: The present invention relates to vaccine composition(s) comprising at least two PspAs from strains selected from at least one family, the family being defined by PspAs from strains belonging to the family having greater than or equal to 50% homology in aligned sequences of a C-terminal region of an alpha helical region of PspA. Additionally, the families are further comprised of clades, wherein PspAs from strains which belong to a clade exhibit greater than 75% sequence homology in aligned sequences of the C-terminal region of the alpha helix of PspA. Vaccine compositions of the present invention preferably comprise a minimum of 4 and a maximum of 6 strains representing a single clade each, and the at least two PspAs are optionally serologically or broadly cross-reactive.Type: GrantFiled: September 30, 2003Date of Patent: March 13, 2007Assignee: The UAB Research FoundationInventors: Robert S. Becker, David E. Briles, Susan Hollingshead
-
Patent number: 7183083Abstract: The invention provides isolated polypeptide and nucleic acid sequences derived from Staphylococcus epidermidis that are useful in diagnosis and therapy of pathological conditions; antibodies against the polypeptides; and methods for the production of the polypeptides. The invention also provides methods for the detection, prevention and treatment of pathological conditions resulting from bacterial infection.Type: GrantFiled: December 1, 2003Date of Patent: February 27, 2007Assignee: WyethInventors: Lynn Doucette-Stamm, David Bush
-
Patent number: 7160990Abstract: A new fibrinogen binding protein or polypeptide originating from coagulase negative staphylococci, biotechnological methods for producing the protein or polypeptide having fibrinogen binding activity and a recombinant DNA molecule coding for the protein (or fragments thereof), and micro-organisms (including viruses) containing this recombinant DNA molecule. The present invention further comprises the therapeutic and diagnostic use of the protein and/or DNA, e.g., a diagnostic kit for determining the presence and/or type of coagulase negative staphylococci and a vaccine composition, comprising the protein or DNA.Type: GrantFiled: March 23, 2004Date of Patent: January 9, 2007Assignee: Biostapro ABInventors: Bengt Guss, Martin Nilsson, Lars Frykberg, Jan-Ingmar Flock, Martin Lindberg
-
Patent number: 7115264Abstract: Monoclonal antibodies which can bind to the Fnbp protein of Staphylococcus aureus and which are generated from a peptide from the D2 region of fibronectin binding protein B (Fnbp) of S. aureus are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. The monoclonal antibodies of the invention are advantageous in that they bind S. aureus in high affinity and thus can be useful in the prevention of the adherence of staph bacteria to host cells by impairing or inhibiting the ability of S. aureus Fnbp to bind to fibronectin. Kits and methods of utilizing the monoclonal antibodies of the invention are also provided.Type: GrantFiled: November 5, 2002Date of Patent: October 3, 2006Assignee: INHIBITEXInventors: Joseph M. Patti, Pratisksha Patel, Andrea Hall, Paul Domanski, Peter Syribeys, Jeff T. Hutchins
-
Patent number: 7087228Abstract: The present invention provides compositions, medicaments, and methods for the treatment or prophylaxis of conditions associated with the binding of Streptococcus mutans to teeth. Specifically, the present invention provides a method for preventing dental caries and infective endocarditis in a subject by treating the subject's oral cavity with a composition or medicament comprising the competence stimulating peptide (CSP) of the causative bacterium, which inhibits the ability of the said bacteria to attach to the surface of teeth. Novel anti-caries compositions using the CSP are also disclosed.Type: GrantFiled: July 2, 2003Date of Patent: August 8, 2006Assignee: University of Southern CaliforniaInventors: Steven D. Goodman, Olga Kay
-
Patent number: 7078042Abstract: Disclosed and claimed are: epitopic regions of Pneumococcal Surface Protein C or “PspC”, different clades of PspC, isolated and/or purified nucleic acid molecules such as DNA encoding a fragment or portion of PspC such as an epitopic region of PspC or at least one epitope of PspC, uses for such nucleic acid molecules, e.g., to detect the presence of PspC or of S. pneumoniae by detecting a nucleic acid molecule therefor in a sample such as by amplification and/or a polymerase chain reaction, vectors or plasmids which contain and/or express such nucleic acid molecles, e.g.Type: GrantFiled: April 23, 1999Date of Patent: July 18, 2006Assignee: UAB Research FoundationInventors: David E. Briles, Susan K. Hollingshead, Alexis Brooks-Walter
-
Patent number: 7067135Abstract: The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, Staphylococcus spp., particularly S. aureus.Type: GrantFiled: April 19, 2001Date of Patent: June 27, 2006Inventor: Naomi Balaban
-
Patent number: 7063980Abstract: A pretreatment kit and a pretreatment kit for saliva in identification and quantitative determination of mutans streptococci by immunochromatography utilizing an antigen-antibody reaction, which can remove aggregation caused by mucin and chain formation of mutans streptococci in saliva in a simple operation and can efficiently flow out a complex of a labeled antibody and mutans streptococci from a porous membrane retaining the labeled antibody, contains (A) a 0.01 to 10 mol/L aqueous solution of sodium hydroxide, (B) a 0.01 to 3 mol/L aqueous solution of tartaric acid and/or citric acid, and (C) a nonionic surface active agent and/or an amphoteric surface active agent, in which the component (C) is mixed with the components (A) and/or (B), or is provided separately, and at least one substance selected from the particular metallic salts is contained in at least one of the components (A), (B) and (C) in an amount of 5 to 25% by weight.Type: GrantFiled: August 22, 2003Date of Patent: June 20, 2006Assignee: GC CorporationInventor: Atsushi Tachino
-
Patent number: 7056510Abstract: The present invention relates to novel vaccines for the prevention or attenuation of infection by Streptococcus pneunoniae. The invention further relates to isolated nucleic acid molecules encoding antigenic polypeptides of Streptococcus pneumoniae. Antigenic polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. The invention additionally relates to diagnostic methods for detecting Streptococcus nucleic acids, polypeptides and antibodies in a biological sample.Type: GrantFiled: October 30, 1997Date of Patent: June 6, 2006Assignee: Human Genome Sciences, Inc.Inventors: Gil H. Choi, Charles A. Kunsch, Steven C. Barash, Patrick J. Dillon, Brian Dougherty, Michael R. Fannon, Craig A. Rosen
-
Patent number: 7045131Abstract: A method and composition for the passive immunization of patients infected with or susceptible to infection from Staphylococcus bacteria such as S. aureus and S. epidermidis infection is provided that includes the selection or preparation of a donor plasma pool with high antibody titers to carefully selected Staphylococcus adhesins or MSCRAMMs, or fragments or components thereof, or sequences with substantial homology thereto. The donor plasma pool can be prepared by combining individual blood or blood component samples which have higher than normal titers of antibodies to one or more of the selected adhesins or other proteins that bind to extracellular matrix proteins, or by administering carefully selected proteins or peptides to a host to induce the expression of desired antibodies, and subsequently recovering the enhanced high titer serum or plasma pool from the treated host.Type: GrantFiled: March 7, 2002Date of Patent: May 16, 2006Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Timothy J. Foster, Magnus Hook
-
Patent number: 7045132Abstract: The invention provides a nucleic acid encoding the 37-kDa protein from Streptococcus pneumoniae. Also provided are isolated nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are antibodies which selectively binds the polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein. Also provided are vaccines comprising immunogenic polypeptides encoded by the nucleic acid encoding the 37-kDa protein and the nucleic acids comprising a unique fragment of at least 10 nucleotides of the 37-kDa protein.Type: GrantFiled: June 4, 2003Date of Patent: May 16, 2006Assignee: The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services, c/o Centers for Disease Control and PreventionInventors: Jacquelyn Sampson, Harold Russell, Jean A. Tharpe, Edwin W. Ades, George M. Carlone
-
Patent number: 7030101Abstract: Compositions and kits comprising combinations of ?-glucans and specific immunoglobulins are disclosed. The compositions and kits are useful in methods of preventing or treating infection by a pathogenic microorganism, in which ?-glucan is administered to a subject, and specific antibodies to a pathogenic microorganism are introduced into the subject.Type: GrantFiled: February 22, 2002Date of Patent: April 18, 2006Assignee: Nabi BiopharmaceuticalsInventors: Viliam Pavliak, Ali Ibrahim Fattom, Robert B. Naso
-
Patent number: 7018986Abstract: The invention provides methods of using beta glucans to treat conditions associated with bone loss or low bone density as well as methods for promoting bone growth in situations where enhanced bone growth is desirable. In the invention methods beta glucans are administered so as to enhance the development of osteoblasts and the inhibition of the development and recruitment of osteoclasts. The inhibition of the recruitment and development of osteoclasts, coupled with the enhancement of osteoblast maturation by beta glucans leads to decreased bone resorption and increased bone formation, making beta glucans ideal agents for the treatment of osteoporosis and other bone resorption diseases.Type: GrantFiled: February 12, 2003Date of Patent: March 28, 2006Assignee: ImmudyneInventors: Nino Sorgente, Harald L. Guenther, Hannelore E. Guenther, Arun K. Bahl
-
Patent number: 7015007Abstract: A substantially pure capsular exopolysaccharide adhesin of coagulase-negative staphylococcal strains, and a gonoral method to prepare such adhesins, are described. Vaccines composed of such adhesins, and uses of such adhesins to produce polyclonal and monoclonal antibodies against such adhesins, are also disclosed. The adhesins are useful in coating polymoric medical materials to prevent colonization by coagulase-negative staphylococcal strains, and as a probe in selecting desirable polymeric medical materials. Such adhesin antibodies are useful in vivo to prevent infection by nosocomial coagulase-negative staphylococcal strains, in assays for the detection of such bacteria, in assays for the estimation of such adhesins in complex mixtures, and as an affinity chromatography matrix.Type: GrantFiled: May 28, 2004Date of Patent: March 21, 2006Assignee: The Brigham and Women's Hospital, Inc.Inventor: Gerald B. Pier
-
Patent number: 6994855Abstract: The invention relates to the isolation of the fibrinogen binding protein gene from Staphylococcus aureus and to the use of the fibrinogen binding protein and antibodies generated against it for wound healing, blocking adherence to indwelling medical devices, immunization or diagnosis of infection.Type: GrantFiled: October 5, 2000Date of Patent: February 7, 2006Assignee: The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near DublinInventors: Timothy James Foster, Damien Leo McDevitt
-
Patent number: 6979446Abstract: Monoclonal antibodies which can bind to the ClfA protein and which are generated from binding subdomains or active fragments of the ClfA protein from Staphylococcus aureus, including the active fragments proteins from its fibrinogen binding domain such as Clf40 protein, the Clf33 protein, or ClfA N3, are provided which can be useful in the treatment and protection against infection from staphylococcal bacteria such as Staphylococcus aureus. In addition, medical instruments can be treated using the monoclonal antibodies of the invention in order to reduce or eliminate the possibility of their becoming infected or further spreading the infection. In particular, the antibodies of the present invention are advantageous because they can prevent adherence of the bacteria to host cells by impairing or inhibiting the ability of S. aureus ClfA to bind to fibrinogen or fibrin, and thus can be utilized in methods or treating or preventing staphylococcal inventions.Type: GrantFiled: January 28, 2002Date of Patent: December 27, 2005Assignee: Inhibitex, Inc.Inventors: Joseph M. Patti, Jeff T. Hutchins, Paul Domanski, Pratiksha Patel, Andrea Hall
-
Patent number: 6923962Abstract: The invention relates to a compound that competitively inhibits binding of CSP to S. mutans histidine kinase. The compound is preferably a peptide or an antibody. The compound is preferably a derivative of [SEQ ID NO:2], a fragment of [SEQ ID NO:2] or a derivative of a fragment of [SEQ ID NO:2].Type: GrantFiled: April 10, 2001Date of Patent: August 2, 2005Inventors: Dennis Cvitkovitch, Peter C. Y. Lau, Yung Hua Li
-
Patent number: 6908619Abstract: The CAMP factor gene of Streptococcus uberis (S. uberis) is described, as well as the recombinant production of CAMP factor therefrom. CAMP factors can be used in vaccine compositions for the prevention and treatment of bacterial infections.Type: GrantFiled: January 21, 1999Date of Patent: June 21, 2005Assignee: University of SaskatchewanInventors: Min Jiang, Andrew A. Potter, Philip Ronald MacLachlan
-
Patent number: 6841154Abstract: Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria, such as S. aureus and to coagulase-negative bacteria, such as S. epidermidis and S. hemolyticus, are provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci, and these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of staphylococcal infections.Type: GrantFiled: June 17, 2002Date of Patent: January 11, 2005Assignees: Inhibitex, Inc., The Provost Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth Near Dublin, Universita'degli Studi di PaviaInventors: Timothy Foster, Fiona Roche, Mark Pallen, Joseph M. Patti, Jeff T. Hutchins, Pietro Speziale
-
Patent number: 6835818Abstract: This invention is directed to mutant SPE-C toxins or fragments thereof, vaccine and pharmaceutical compositions, and methods of using the vaccine and pharmaceutical compositions. The preferred SPE-C toxin has at least one amino acid change and is substantially non-lethal compared with the wild type SPE-C toxin. The mutant SPE-C toxins can form vaccine compositions useful to protect animals against the biological activities of wild type SPE-C toxin.Type: GrantFiled: July 14, 1999Date of Patent: December 28, 2004Assignee: Regents of the University of MinnesotaInventors: Patrick M. Schlievert, Douglas Ohlendorf, David T. Mitchell, Pamala J. Gahr
-
Publication number: 20040223973Abstract: This invention relates to conjugates of the Vi polysaccharide of S. typhi with the carrier Pseudomonas aeruginosa recombinant exoprotein A (rEPA), and compositions thereof, and to methods of using of these conjugates and/or compositions thereof for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, S. typhi bacterial infections. The conjugates, and compositions thereof, are useful as vaccines to induce serum antibodies againt S. typhi and are useful to prevent and/or treat illnesses caused by S. typhi.Type: ApplicationFiled: June 10, 2004Publication date: November 11, 2004Applicant: The Gov. of the USA, as represented by the Secretary, Department of Health and Human ServicesInventors: Zuzana Kossaczka, Shousun Chen Szu, John B. Robbins, Rachel Schneerson, Joseph Shiloach
-
Patent number: 6803035Abstract: A food product and method for treating and preventing diarrhea in a subject animal suffering from or susceptible to diarrhea. The method comprises administering an egg product to the subject animal wherein the egg product is obtained from a hyperimmunized avian.Type: GrantFiled: January 22, 2002Date of Patent: October 12, 2004Assignee: Arkion Life SciencesInventors: Hellen Chaya Greenblatt, Orn Adalsteinsson, David A. Brodie, Henry Jacoby
-
Patent number: 6790661Abstract: The invention provides methods for screening for the presence of a clinically relevant amount of bacteria in donor blood or a blood product from a donor mammal, particularly blood or a blood product that will be transferred from the donor mammal to a recipient mammal. The method comprises contacting a sample of the donor blood or a blood product with a set of binding agents that comprises binding agents that specifically bind to Gram-negative bacterial antigen and/or binding agents that specifically bind to Gram-positive bacterial antigen, and determining binding of the set of binding agents to the sample, wherein binding indicates the presence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product and no binding indicates the absence of a clinically relevant amount of Gram-positive bacteria and/or Gram-negative bacteria in the donor blood or blood product.Type: GrantFiled: July 14, 2000Date of Patent: September 14, 2004Assignee: Verax Biomedical, Inc.Inventor: Timothy T. Goodnow
-
Patent number: 6790448Abstract: Isolated peptide sequences and proteins containing these sequences are provided which are useful in the prevention and treatment of infection caused by Gram-positive bacteria. The peptide sequences have been shown to be highly conserved motifs in the surface proteins of Gram-positive bacteria, and these consensus sequences include amino acid sequences such as LPXTG (SEQ ID NO:13), ALKTGKIDIIISGMTSTPERKK (SEQ ID NO:14), VEGAWEKPVAEAYLKQN (SEQ ID NO:15), and EYAGVDIDLAKKIAK (SEQ ID NO:16). By virtue of the highly conserved regions, the sequences and the proteins including these sequences can be utilized to generate antibodies which can recognize these highly conserved motifs and the proteins containing them and thus be useful in the treatment or prevention of a wide range of infections caused by Gram-positive bacteria.Type: GrantFiled: May 8, 2002Date of Patent: September 14, 2004Assignee: The Texas A&M University System UniversityInventors: Yi Xu, Magnus A. O. Hook
-
Patent number: 6790446Abstract: The present invention relates to vaccines comprising antiserum raised against a flagellaless Campylobacter strain for the prevention of Campylobacter colonization in animals. The invention also relates to antigenic Campylobacter proteins visible in a Western blot of Campylobacter jejuni protein after incubation of said Western blot with antibodies against a flagellaless mutant of Campylobacter jejuni and not visible after incubation of said blot with antibodies against wild type Campylobacter jejuni, and to their use in vaccines and the manufacturing thereof. The invention further relates to vaccines comprising such proteins and antibodies against such proteins. The invention further relates to the use of such Campylobacter proteins and to antiserum and antibodies raised against Campylobacter antigens for the preparation of vaccines. Finally, the invention relates to methods for the preparation of such vaccines.Type: GrantFiled: July 10, 2002Date of Patent: September 14, 2004Assignee: Akzo Nobel, NVInventors: Antonius Arnoldus Christiaan Jacobs, Johannes Franciscus van den Bosch, Petrus Johannes Maria Nuijten